Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sinovac Receives $12 Million Vaccine Order

publication date: Apr 28, 2009

Sinovac Biotech (北京科兴生物制品有限公司) received an order for 87 million RMB ($12.8 million) of its inactivated hepatitis A vaccine, Healive® from China's Ministry of Public Health (MOH). In 2008, Sinovac recorded revenues of $46.5 million, 88% of which came from Healive. To improve public health, the MOH is undertaking a hepatitis A vaccination campaign that will cover young children from 18 months to 12 years old in 32 cities or counties in nine provinces. More details...

Stock Symbol: (NYSE Amex: SVA)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital